Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations

Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations

10.1097/JTO.0000000000000156

Saved in:

Bibliographic Details
Main Authors:	Haaland, B., Tan, P.S., De Castro Jr., G., Lopes, G.
Other Authors:	DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE
Format:	Article
Published:	2016
Subjects:	Epidermal growth factor receptor-activating mutations Meta-analysis Non-small-cell lung cancer Tyrosine kinase inhibitors
Online Access:	http://scholarbank.nus.edu.sg/handle/10635/124813
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
by: Yeo, W.-L., et al.
Published: (2011)

The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: A single South East Asian laboratory's analysis of 670 cases
by: Pang, B., et al.
Published: (2014)

Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis
by: Budman, D.R., et al.
Published: (2014)

Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments
by: Wang D.D., et al.
Published: (2019)

Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma
by: Lee, S.-C., et al.
Published: (2012)

EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
by: Ma, L, et al.
Published: (2020)

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
by: Ku, G.Y., et al.
Published: (2016)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer
by: Ali, A, et al.
Published: (2020)

EGFR activation monitored by SW-FCCS in live cells
by: Ma, X., et al.
Published: (2014)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
by: Sudo, M., et al.
Published: (2014)

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach
by: Salto-Tellez, M., et al.
Published: (2014)

Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis
by: Teo, Y.L., et al.
Published: (2014)

KIT gene mutation analysis in solid tumours: Biology, clincial applications and trends in diagnostic reporting
by: Tay, C.M., et al.
Published: (2014)

How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?
by: Chan, A., et al.
Published: (2014)

Phosphoproteomics, oncogenic signaling and cancer research
by: Chong, P.-K., et al.
Published: (2014)

Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations
by: Tan, P.S, et al.
Published: (2020)

Tannic acid, a potent inhibitor of epidermal growth factor receptor tyrosine kinase
by: Yang, E.B., et al.
Published: (2014)

Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives
by: Yang, E.B., et al.
Published: (2014)

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
by: De Lima Lopes Jr., G., et al.
Published: (2016)

Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: Results of a meta-analysis of randomized controlled trials
by: Soo, R.A., et al.
Published: (2014)

Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung Cancer
by: Ho, Y.S, et al.
Published: (2020)

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)
by: Lim, E.H., et al.
Published: (2011)

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)
by: Lim, E.H., et al.
Published: (2014)

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
by: Nahar, R, et al.
Published: (2020)

Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer
by: Collins, Denis M., et al.
Published: (2020)

Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer
by: Chin, L.P., et al.
Published: (2014)

Design and synthesis of receptor tyrosine kinase inhibitors for anticancer treatment
by: Chawannuch Mudjupa
Published: (2023)

Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
by: Chin, T.-M., et al.
Published: (2021)

Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing
by: Ho, H.K., et al.
Published: (2014)

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
by: Shimamura, T, et al.
Published: (2020)

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: Possible implications for targeted therapy
by: Teng, Y.H.-F, et al.
Published: (2020)

MECHANISMS OF HYPOXIA-INDUCED GROWTH AND TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKEMIA
by: MANJERI ADITI SUBRAMANIAM
Published: (2019)

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
by: Kim, H.R., et al.
Published: (2014)

Impact of epidermal growth factor receptor sensitizing mutations on outcomes of patients with non-small cell lung cancer treated with definitive thoracic radiation therapy: A systematic review and meta-analysis
by: Soon, Y.Y, et al.
Published: (2020)

Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis
by: Lee, Chia Ching, et al.
Published: (2022)

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer
by: Tsui, D.W.Y, et al.
Published: (2020)

Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer
by: Collins, D.M., et al.
Published: (2021)

EXPLORING RECEPTOR TYROSINE KINASES IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
by: BHAVE SAYALI SHRIVARDHAN
Published: (2023)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
by: Park, Keunchil, et al.
Published: (2022)

Functional Effects of a Novel BIM Deletion Polymorphism in Mediating Resistance to Tyrosine Kinase Inhibitors in Cancer
by: JUAN WEN CHUN
Published: (2014)